Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells

International Journal of Cancer

Volumn 127, Issue 3, 2010, Pages 696-706

  Fischgräbe, Jeanett ^a   Götte, Martin ^a   Michels, Katharina ^a   Kiesel, Ludwig ^a   Wülfing, Pia ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Breast cancer; Endothelin A receptor; Endothelin 1; HER2; Targeted therapy

Indexed keywords

ATRASENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER CELL; CANCER INVASION; CELL INVASION; CELL PROLIFERATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG SYNERGISM; ENDOTHELIN-1; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENES, ERBB-2; HUMANS; NEOPLASM METASTASIS; PHOSPHORYLATION; PYRROLIDINES; RECEPTOR, ENDOTHELIN A;

EID: 77954449908     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25076     Document Type: Article

References (53)

1. Fischgräbe J, Wülfing P. Targeted therapies in breast cancer: established drugs and recent developments. Curr Clin Pharmacol 2008;3:85-98.
2. Lev DC, Ruiz M, Mills L, McGary EC, Price JE, Bar-Eli M. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther 2003;2:753-63.
3. Rajput A, Koterba AP, Kreisberg JI, Foster JM, Willson JK, Brattain MG. A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo. Cancer Res 2007;67:665-73.
4. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007;608:1-22.
5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
6. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
7. Ménard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E. Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci 2004;61:2965-78.
8. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
9. Lonardo F, Di Marco E, King CR, Pierce JH, Segatto O, Aaronson SA, Di Fiore PP. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Biol 1990;2:992-1003.
10. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, Yarden Y. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 1999;96:4995-5000.
11. Wada T, Qian XL, Greene MI. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 1990;61:1339-47. (Pubitemid 20208837)
12. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene 2007;26:3637-43.
13. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27.
14. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007;18:977-84.
15. O'Shaughnessy J, Blackwell KL, Burstein H, Storniolo AM, Sledge G, Baselga J, Koehler M, Laabs S, Florance A, Roychowdhury D. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 2008;26 (Suppl; abstract 1015).
16. Nahta R, Hung MC, Esteva FJ. The HER- 2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004;64:2343-6.
17. Gelmon KA, Fumoleau P, Verma S, Wardley AM, Conte PF, Miles D, Gianni L, McNally VA, Ross G, Baselga J. Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. J Clin Oncol 2008;26(Suppl; abstract 1026).
18. Modi S, Sugarman S, Stopeck A, Linden H, Ma W, Kersey K, Johnson RG, Rosen N, Hannah AL, Hudis CA. Phase II trial of the Hsp90 inhibitor tanespimycin (tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC). J Clin Oncol 2008;26 (Suppl; abstract 1027).
19. Wu K, Wang C, D'Amico M, Lee RJ, Albanese C, Pestell RG, Mani S. Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and akt signaling pathways. Mol Cancer Ther 2002;1:695-706.
20. Shichiri M, Hirata Y, Nakajima T, Ando K, Imai T, Yanagisawa M, Masaki T, Marumo F. Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines. J Clin Invest 1991;87:1867-71.
21. Bagnato A, Tecce R, Moretti C, Di Castro V, Spergel D, Catt KJ. Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells. Clin Cancer Res 1995;1:1059-66.
22. Nelson JB, Udan MS, Guruli G, Pflug BR. Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia 2005;7:631-7. (Pubitemid 41099416)
23. Salani D, Taraboletti G, Rosanò L, Di Castro V, Borsotti P, Giavazzi R, Bagnato A. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 2000;157:1703-11.
24. Shankar A, Loizidou M, Aliev G, Fredericks S, Holt D, Boulos PB, Burnstock G, Taylor I. Raised endothelin 1 levels in patients with colorectal liver metastases. Br J Surg 1998;85:502-6.
25. Smollich M, Götte M, Kersting C, Fischgräbe J, Kiesel L, Wülfing P. Selective ET(A)R antagonist atrasentan inhibits hypoxia-induced breast cancer cell invasion. Breast Cancer Res Treat 2008;108:175-82.
26. Bagnato A, Cirilli A, Salani D, Simeone P, Muller A, Nicotra MR, Natali PG, Venuti A. Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res 2002;62:6381-4. (Pubitemid 35364090)
27. Rosanò L, Spinella F, Di Castro V, Natali PG, Bagnato A. Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: efficacy of cytotoxic agents is markedly enhanced by coadministration with atrasentan. J Cardiovasc Pharmacol 2004;44:132-5.
28. Banerjee S, Hussain M, Wang Z, Saliganan A, Che M, Bonfil D, Cher M, Sarkar FH. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 2007;67:3818-26.
29. Wülfing P, Persigehl T, Gotte M, Meyer V, Wülfing C, Kersting C, Sonntag B, Kiesel L, Bremer C. Targeting the endothelin-Areceptor inhibits breast carcinoma growth in vivo. AACR Meeting Abstracts 2005;2005:356-b.
30. Wülfing P, Diallo R, Kersting C, Wülfing C, Poremba C, Rody A, Greb RR, Böcker W, Kiesel L. Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up. Clin Cancer Res 2003;9:4125-31.
31. Wülfing P, Tio J, Kersting C, Sonntag B, Buerger H, Wülfing C, Euler U, Boecker W, Tulusan AH, Kiesel L. Expression of endothelin-A-receptor predicts unfavourable response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 2004;91:434-40.
32. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-45. (Pubitemid 17082655)
33. Wülfing P, Götte M, Sonntag B, Kersting C, Schmidt H, Wülfing C, Buerger H, Greb R, Böcker W, Kiesel L. Overexpression of endothelin-A-receptor in breast cancer: regulation by estradiol and cobalt-chloride induced hypoxia. Int J Oncol 2005;26:951-60.
34. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996;379:557-60.
35. Vacca F, Bagnato A, Catt KJ, Tecce R. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res 2000;60:5310-7.
36. Boerner JL, Biscardi JS, Silva CM, Parsons SJ. Transactivating agonists of the EGF receptor require tyr 845 phosphorylation for induction of DNA synthesis. Mol Carcinog 2005;44:262-73.
37. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-37.
38. Beguinot L, Lyall RM, Willingham MC, Pastan I. Down-regulation of the epidermal growth factor receptor in KB cells is due to receptor internalization and subsequent degradation in lysosomes. Proc Natl Acad Sci USA 1984;81:2384-8. (Pubitemid 14148263)
39. Inoue A, Yanagisawa M, Takuwa Y, Mitsui Y, Kobayashi M, Masaki T. The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression. J Biol Chem 1989;264:14954-9. (Pubitemid 19237323)
40. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 2001;61:4744-9.
41. Takahashi M, Fukuda K, Shimada K, Barnes K, Turner AJ, Ikeda M, Koike H, Yamamoto Y, Tanzawa K Localization of rat endothelin-converting enzyme to vascular endothelial cells and some secretory cells. Biochem J 1995;311 (Part 2):657-65.
42. Tan M, Li P, Klos KS, Lu J, Lan KH, Nagata Y, Fang D, Jing T, Yu D. ErbB2 promotes src synthesis and stability: novel mechanisms of src activation that confer breast cancer metastasis. Cancer Res 2005;65:1858-67.
43. Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, Hung MC. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004;6:459-69.
44. Sakamoto Y, Doi Y, Ohsato K, Fujimoto S. Immunoelectron microscopy on the localization of endothelin in the umbilical vein of perinatal rabbits. Anat Rec 1993;237:482-8. (Pubitemid 23339101)
45. Ozaka T, Doi Y, Kayashima K, Fujimoto S. Weibel-palade bodies as a storage site of calcitonin gene-related peptide and endothelin-1 in blood vessels of the rat carotid body. Anat Rec 1997;247:388-94.
46. Roetger A, Merschjann A, Dittmar T, Jackisch C, Barnekow A, Brandt B. Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model. Am J Pathol 1998;153:1797-806.
47. Grimshaw MJ, Hagemann T, Ayhan A, Gillett CE, Binder C, Balkwill FR. A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res 2004;64:2461-8.
48. Binder C, Hagemann T, Sperling S, Schulz M, Pukrop T, Grimshaw MJ, Ehrenreich H. Stromal endothelin B receptordeficiency inhibits breast cancer growth and metastasis. Mol Cancer Ther 2009;8:2452-2460.
49. Price DJ, Avraham S, Feuerstein J, Fu Y, Avraham HK. The invasive phenotype in HMT-3522 cells requires increased EGF receptor signaling through both PI 3-kinase and ERK 1,2 pathways. Cell Commun Adhes 2002;9:87-102. (Pubitemid 36032977)
50. Rosanò L, Spinella F, Salani D, Di Castro V, Venuti A, Nicotra MR, Natali PG, Bagnato A. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res 2003;63:2447-53. (Pubitemid 36605182)
51. Clynes RA, Towers TL, Presta LG, Ravetch JV Inhibitory fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6.
52. Barok M, Isola J, Pályi-Krekk Z, Nagy P, Juhász I, Vereb G, Kauraniemi P, Kapanen A, Tanner M, Vereb G, Szöllösi J. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther 2007;6:2065-72.
53. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006;94:259-67.